Skip to main content

Table 3 Off-label use of tocilizumab in pediatric patients with non-JIA rheumatic diseases except Takayasu arteritis and JIA-associated uveitis

From: Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Disease n Age, years Efficacy of TCZ Dose of TCZ Adverse effect of TCZ References
Juvenile SLE 1 13 Improved arthritis and inflammatory markers Reduction of GC dose 400 mg/month No [21]
Juvenile dermatomyositis 1 12 Improved arthritis 8 mg/kg/4 weeks No [28]
Takayasu arteritis 12 3–16 Improved symptoms and inflammatory marker Reduction of GC dose No FDG uptake 8 mg/kg/3–4 weeks No [34,35,36,37,38]
Juvenile localized scleroderma 7 6–13 Improved disease activity and inhibition of progression ≥30 kg: 8 mg/kg
< 30 kg: 12 mg/kg every 4 weeks
No [47, 48]
Autoimmune encephalitis 3 10, 12, 15 Improved neurological symptoms without recurrence 8–12 mg/kg/4 weeks No [51]
Kawasaki’s disease 4 1–8 Improved symptoms and inflammatory markers 8 mg/kg once Giant coronary artery aneurysm (2) [55]
JIA-associated uveitis   8–38 Improved visual acuity
Reduction of GC dose
8 mg/kg/4 weeks Thrombocytopenia (1), pneumonia, thrombocytopenia, and hemolytic anemia (1), viral conjunctivitis and bullous impetigo (1) [57, 58, 60, 62]
Multicentric Castleman’s disease 4 1–16 Sustained remission 8 mg/kg/2 weeks
10 mg/kg three times
8 mg/kg/2 weeks
Herpes zoster (1) [64,65,66]
Amyloid A amyloidosis 3 19, 26, 29 Improved symptoms and inflammatory markers 8 mg/kg/2–4 weeks No [68, 69]
Cytokine release syndrome (CRS) 15 7–16 Improved symptoms and inflammatory markers 8 mg/kg 1–3 times No [72, 73]
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) 1 4 Improved symptoms and inflammatory markers 8 mg/kg/month No [74]
H syndrome (PHID) 4 3–19 Improved symptoms and inflammatory markers IV: 8 mg/kg
SQ: 10.8–12 mg/kg every 2 weeks
No [76, 77]
Undifferentiated autoinflammatory disease with interstitial pneumonitis 1 15 Improved symptoms and reduction of ground-glass opacity on CT 8 mg/kg/month No [78]
  1. JIA juvenile idiopathic arthritis, SLE systemic lupus erythematosus, TCZ tocilizumab, GC glucocorticoids, IV intravenous, SQ subcutaneous, CT computed tomography